Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Adalat CC Extended Release 30 g Tabs 100 By Bayer Pharma

Image 0 of Adalat CC Extended Release 30 g Tabs 100 By Bayer Pharma

Adalat CC Extended Release 30 g Tabs 100 By Bayer Pharma

Call for Price

Adalat CC Extended Release 30 g Tabs 100 By Bayer Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD3634441/RXB10098672
Size : 100
Selling UoM : EA
NDC: 50419-0701-05
UPC Barcode : 350419701051
Supplier:0050001919 BAYER HC PHARM INC-ORDER DEPT
Supplier Material : 070105
Generic Code : 012059 NIFEDIPINE ORAL TABLET ER 30 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Bra

Have a question?

  Call for Price

Product Description.:

ADALAT CC, 30
Tablet , film-coated , pink , round round

Generic Name: nifedipine
Dosage Form: extended release tablets
ADALAT?CC
(nifedipine)
Extended Release Tablets
For Oral Use
Adalat CC Description

ADALAT? CC is an extended release tablet dosage form of the calcium channel blocker nifedipine.

Nifedipine is a yellow crystalline substance, practically insoluble in water but soluble in ethanol. It has a molecular weight of 346.3. Adalat CC tablets consist of an external coat and an internal core. Both contain nifedipine, the coat as a slow release formulation and the core as a fast release formulation. Adalat CC tablets contain either 30, 60, or 90 mg of nifedipine for once-a-day oral administration.

Inert ingredients in the formulation are: hydroxypropylcellulose, lactose, corn starch, crospovidone, microcrystalline cellulose, silicon dioxide, and magnesium stearate. The inert ingredients in the film coating are: hypromellose, polyethylene glycol, ferric oxide, and titanium dioxide.

INDICATION AND USAGE

Adalat CC is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Contraindications

Known hypersensitivity to nifedipine.
Warnings
Excessive Hypotension:

Although in most patients the hypotensive effect of nifedipine is modest and well tolerated, occasional patients have had excessive and poorly tolerated hypotension. These responses have usually occurred during initial titration or at the time of subsequent upward dosage adjustment, and may be more likely in patients using concomitant beta-blockers.

Severe hypotension and/or increased fluid volume requirements have been reported in patients who received immediate release capsules together with a beta-blocking agent and who underwent coronary artery bypass surgery using high dose fentanyl anesthesia. The interaction with high dose fentanyl appears to be due to the combination of nifedipine and a beta-blocker, but the possibility that it may occur with nifedipine alone, with low doses of fentanyl, in other surgical procedures, or with other narcotic analgesics cannot be ruled out. In nifedipine-treated patients where surgery using high dose fentanyl anesthesia is contemplated, the physician should be aware of these potential problems and, if the patient?s condition permits, sufficient time (at least 36 hours) should be allowed for nifedipine to be washed out of the body prior to surgery.
Increased Angina and/or Myocardial Infarction:

Rarely, patients, particularly those who have severe obstructive coronary artery disease, have developed well-documented increased frequency, duration and/or severity of angina or acute myocardial infarction upon starting nifedipine or at the time of dosage increase. The mechanism of this effect is not established.
Beta-Blocker Withdrawal:

When discontinuing a beta-blocker it is important to taper its dose, if possible, rather than stopping abruptly before beginning nifedipine. Patients recently withdrawn from beta blockers may develop a withdrawal syndrome with increased angina, probably related to increased sensitivity to catecholamines. Initiation of nifedipine treatment will not prevent this occurrence and on occasion has been reported to increase it.
Congestive Heart Failure:

Rarely, patients (usually while receiving a beta-blocker) have developed heart failure after beginning nifedipine. Patients with tight aortic stenosis may be at greater risk for such an event, as the unloading effect of nifedipine would be expected to be of less benefit to these patients, owing to their fixed impedance to flow across the aortic valve.